|
|
135 Wood Street
West Haven, CT 06516 USA
phone:310-486-5677
fax:630-604-6402
|
|
| Symbol |
NNVC |
| Exchange |
OTCBB |
| Founded |
2005 |
| Employees |
10 |
|
|
| nanoviricides.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Anti-viral drugs to fight HIV, influenza, and other infections |
|
| Management |
| Eugene Seymour, MD, MPH, CEO; Anil R. Diwan, PhD, Chairman & President; Randall Barton, PhD, CSO; Jayant Tatake, PhD, Vice President R&D; Krishna Menon, PhD, VMD, MRCS, Chief Regulatory Office, Consulting, |
| |
|
|
|
|
|
|
|
| Keywords |
| anti-viral drugs, HIVAIDS, dengue, influenza, herpes, adenovirus, keratitis, Immunology, DrugDelivery |
|
|
|
|
|
|
| Description |
|
NanoViricides Inc. is a pre-clinical biotech company that develops drugs to combat viral infections. The Company designs nanoviricides that fool viruses into attaching to them in that same way that viruses typically attach to the receptors on a cell surface; once attached, the nanoviricide causes the virus to lose the protein coat it would need to bind to the human cell that it otherwise would, effectively neutralizing it without engaging the immune system. The Company has drug candidates against HIV, seasonal influenzas and bird flu, herpes, viral eye diseases, and dengue viruses, and has nominated a clinical candidate in its FluCide program. The research team at this earlier-stage biotechnology company possesses the combined expertise of having performed research, development, and regulatory processing for over 25 drugs, of which ten are approved. |
|
| Products / Services |
FluCide-I (Influenza A)
HivCide-I (HIV/AIDS)
DengiCide-I (Dengue/dengue hemorrhagic fever)
HerpiCide-I (For ocular herpes infections)
EKC-Cide-I (For ocular adenovirus infections)
|
|
| Technology / Differentiation |
| NanoViricides Inc. has full license to TheraCour technologies for developing nanotechnology-based targeted anti-viral therapeutics. |
|
| Market / Customers |
individuals, governments
|
|
| Competitors / Substitutes / Alternatives |
No one else has a platform technology to rapidly create and deploy anti-viral drugs
|
|
| Strategy |
Develop and test drug candidates in animals, then file data with the FDA for permission to move to human trials. We will consider licensing each drug after the completion of Phase 2a human trials
|
|
| Revenue / Funding |
| Spent $17M in 5 1/2 years with 9 drugs in pipeline of which there are 5 lead candidates for eventual FDA submission. At historical spending levels, the Company has 3 years of cash in the bank although the path to the FDA will require increased expenditures on a monthly basis. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
